Payment overview · 2025
General Payments
$3,468.64
169 reported records · 36 companies
Healthcare provider profile · identity verified
Scott Yarmark, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · EAST NORRITON, PA · NPI 1265548648
Verified facts
What the public records show
CMS Open Payments records show Scott Yarmark, D.O. received $3,468.64 in general payments during 2025 across 169 reported records.
GlaxoSmithKline, LLC. accounted for 8.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 56 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Shingrix, Trelegy Ellipta, Vraylar, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Zenpep by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 853 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $290.77 | 8.4% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $272.66 | 7.9% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $272.47 | 7.9% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $243.87 | 7.0% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $241.05 | 7.0% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $211.90 | 6.1% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $156.46 | 4.5% | 11 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $145.98 | 4.2% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $141.50 | 4.1% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $140.51 | 4.0% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.01 | 3.6% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $119.26 | 3.4% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $115.74 | 3.3% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $104.67 | 3.0% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $84.40 | 2.4% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $84.16 | 2.4% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $75.41 | 2.2% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $72.87 | 2.1% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $66.98 | 1.9% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $58.79 | 1.7% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $49.10 | 1.4% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $44.46 | 1.3% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $44.07 | 1.3% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $41.32 | 1.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $32.26 | 0.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $27.67 | 0.8% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.20 | 0.8% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $25.57 | 0.7% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.26 | 0.7% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.23 | 0.6% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $19.57 | 0.6% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $19.33 | 0.6% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $18.36 | 0.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.67 | 0.5% | 1 | 2025 |
| MEDICOMP INC | Unresolved — no canonical attribution shown | $16.54 | 0.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.57 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,468.64 | 169 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $261.02 | 13 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $200.14 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $192.99 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $188.17 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $156.46 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $156.46 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $150.66 | 10 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $145.98 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $145.56 | 8 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $141.50 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $140.51 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $124.01 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $121.81 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $121.81 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $105.71 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $105.00 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $104.67 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $101.90 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $83.35 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $75.41 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $72.87 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $66.98 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $62.45 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $62.00 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $58.79 | 3 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $49.10 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $48.00 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.83 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $44.46 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $44.37 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $44.37 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $44.37 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $44.07 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $42.61 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $41.32 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $35.91 | 2 | 2025 |
Source payment records
|
|||||
| General - DBS Normalized: general dbs |
Device | Boston Scientific Corporation | $32.26 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.75 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $27.67 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $26.20 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $25.57 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $25.57 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $25.26 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $22.23 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| TELEPATCH CARDIAC MONITOR Normalized: telepatch cardiac monitor |
Device | MEDICOMP INC | $16.54 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $4.44 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $4.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 853 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 152 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 125 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 141 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 148 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 79 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 29 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 119 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
86 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
152 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
74 | 74 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
29 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
119 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
141 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
148 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
171 | 24 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 22 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
853 | 132 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
125 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1158 | 291 |
| Eliquis | Apixaban | 853 | 132 |
| Amlodipine Besylate | Amlodipine Besylate | 830 | 188 |
| Levothyroxine Sodium | Levothyroxine Sodium | 787 | 154 |
| Metoprolol Succinate | Metoprolol Succinate | 783 | 191 |
| Lisinopril | Lisinopril | 653 | 155 |
| Gabapentin | Gabapentin | 604 | 130 |
| Pantoprazole Sodium | Pantoprazole Sodium | 552 | 148 |
| Losartan Potassium | Losartan Potassium | 498 | 119 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 498 | 136 |
| Furosemide | Furosemide | 453 | 83 |
| Sertraline Hcl | Sertraline Hcl | 447 | 81 |
| Trazodone Hcl | Trazodone Hcl | 438 | 101 |
| Metformin Hcl | Metformin Hcl | 407 | 97 |
| Tamsulosin Hcl | Tamsulosin Hcl | 389 | 102 |
| Mirtazapine | Mirtazapine | 375 | 81 |
| Omeprazole | Omeprazole | 321 | 72 |
| Clopidogrel | Clopidogrel Bisulfate | 317 | 75 |
| Metoprolol Tartrate | Metoprolol Tartrate | 301 | 74 |
| Duloxetine Hcl | Duloxetine Hcl | 274 | 69 |
| Carvedilol | Carvedilol | 264 | 64 |
| Famotidine | Famotidine | 262 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 245 | 62 |
| Simvastatin | Simvastatin | 230 | 48 |
| Quetiapine Fumarate | Quetiapine Fumarate | 197 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 194 | 50 |
| Potassium Chloride | Potassium Chloride | 184 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 180 | 31 |
| Divalproex Sodium | Divalproex Sodium | 177 | 29 |
| Bumetanide | Bumetanide | 176 | 45 |
| Trulicity | Dulaglutide | 171 | 24 |
| Methylprednisolone | Methylprednisolone | 165 | 131 |
| Oxycodone Hcl | Oxycodone Hcl | 162 | 37 |
| Allopurinol | Allopurinol | 153 | 36 |
| Farxiga | Dapagliflozin Propanediol | 152 | 31 |
| Mounjaro | Tirzepatide | 148 | 27 |
| Xarelto | Rivaroxaban | 144 | 18 |
| Baclofen | Baclofen | 142 | 42 |
| Jardiance | Empagliflozin | 141 | 29 |
| Lorazepam | Lorazepam | 139 | 44 |
| Levetiracetam | Levetiracetam | 137 | 22 |
| Buspirone Hcl | Buspirone Hcl | 135 | 30 |
| Finasteride | Finasteride | 130 | 28 |
| Olanzapine | Olanzapine | 129 | 16 |
| Gemtesa | Vibegron | 125 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 124 | 30 |
| Meloxicam | Meloxicam | 119 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 119 | 29 |
| Metformin Hcl Er | Metformin Hcl | 111 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 49 |
| Celecoxib | Celecoxib | 101 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 99 | 25 |
| Aripiprazole | Aripiprazole | 98 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 44 |
| Midodrine Hcl | Midodrine Hcl | 98 | 23 |
| Donepezil Hcl | Donepezil Hcl | 97 | 20 |
| Warfarin Sodium | Warfarin Sodium | 95 | 13 |
| Latanoprost | Latanoprost | 94 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 94 | 49 |
| Amiodarone Hcl | Amiodarone Hcl | 92 | 26 |
| Ibandronate Sodium | Ibandronate Sodium | 91 | 26 |
| Memantine Hcl | Memantine Hcl | 89 | 15 |
| Spironolactone | Spironolactone | 88 | 22 |
| Ibuprofen | Ibuprofen | 87 | 23 |
| Azithromycin | Azithromycin | 86 | 67 |
| Myrbetriq | Mirabegron | 86 | 17 |
| Prednisone | Prednisone | 85 | 40 |
| Bupropion Xl | Bupropion Hcl | 83 | 29 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 81 | 31 |
| Valsartan | Valsartan | 81 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 80 | 21 |
| Montelukast Sodium | Montelukast Sodium | 79 | 22 |
| Ozempic | Semaglutide | 79 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 18 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 74 | 74 |
| Ezetimibe | Ezetimibe | 72 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 71 | 12 |
| Enoxaparin Sodium | Enoxaparin Sodium | 70 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 68 | 21 |
| Tramadol Hcl | Tramadol Hcl | 65 | 32 |
| Alendronate Sodium | Alendronate Sodium | 64 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 64 | 13 |
| Topiramate | Topiramate | 62 | 19 |
| Alprazolam | Alprazolam | 61 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 28 |
| Glimepiride | Glimepiride | 60 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 13 |
| Incruse Ellipta | Umeclidinium Bromide | 56 | suppressed |
| Torsemide | Torsemide | 56 | 18 |
| Nystatin | Nystatin | 54 | 34 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 52 | 39 |
| Morphine Sulfate Er | Morphine Sulfate | 51 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 13 |
| Risperidone | Risperidone | 50 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 48 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 48 | 12 |
| Nifedipine Er | Nifedipine | 47 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 41 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Januvia | Sitagliptin Phosphate | 45 | 13 |
| Linzess | Linaclotide | 44 | 11 |
| Memantine Hcl Er | Memantine Hcl | 43 | suppressed |
| Pregabalin | Pregabalin | 43 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | suppressed |
| Amoxicillin | Amoxicillin | 41 | 19 |
| Brilinta | Ticagrelor | 41 | suppressed |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 24 |
| Lansoprazole | Lansoprazole | 39 | suppressed |
| Cephalexin | Cephalexin | 38 | 34 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 38 | 14 |
| Clonazepam | Clonazepam | 37 | 14 |
| Movantik | Naloxegol Oxalate | 37 | suppressed |
| Novolog Flexpen | Insulin Aspart | 37 | 13 |
| Prazosin Hcl | Prazosin Hcl | 37 | suppressed |
| Ramipril | Ramipril | 36 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 35 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 35 | 19 |
| Lovastatin | Lovastatin | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | 11 |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 32 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 11 |
| Atenolol | Atenolol | 31 | suppressed |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 25 |
| Digoxin | Digoxin | 30 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 29 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | 13 |
| Dexamethasone | Dexamethasone | 28 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 14 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 28 | suppressed |
| Imipenem-Cilastatin Sodium | Imipenem/Cilastatin Sodium | 28 | suppressed |
| Lidocaine | Lidocaine | 28 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 28 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 19 |
| Anastrozole | Anastrozole | 27 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 19 |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 25 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Erythromycin | Erythromycin Base | 24 | 17 |
| Morphine Sulfate | Morphine Sulfate | 24 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 23 | 15 |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 14 |
| Tradjenta | Linagliptin | 23 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 16 |
| Loperamide | Loperamide Hcl | 21 | 14 |
| Sucralfate | Sucralfate | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Nystop | Nystatin | 20 | 16 |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 19 | 19 |
| Flecainide Acetate | Flecainide Acetate | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 15 |
| Repaglinide | Repaglinide | 19 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 18 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 17 |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Klayesta | Nystatin | 17 | suppressed |
| Budesonide | Budesonide | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 13 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Nadolol | Nadolol | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Zonisamide | Zonisamide | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Bicalutamide | Bicalutamide | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | 12 |
| Dantrolene Sodium | Dantrolene Sodium | 13 | suppressed |
| Lamotrigine Er | Lamotrigine | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 12 | suppressed |
| Humira(Cf) | Adalimumab | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 11 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Alogliptin | Alogliptin Benzoate | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vyzulta | Latanoprostene Bunod | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,468.64 · 169 records | GlaxoSmithKline, LLC. | ABRYSVO, ACCRUFER, AIRSUPRA, AUSTEDO XR, Arikayce, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, GEMTESA, General - DBS, IBSRELA, INJECTAFER, INSPIRE, JARDIANCE, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, ONPATTRO, OTEZLA, Ocrevus Zunovo, Ohtuvayre, Ozempic, PREVNAR 20, PROCLAIM, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, Symbravo, TELEPATCH CARDIAC MONITOR, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VOQUEZNA, VRAYLAR, VYNDAMAX, VYNDAQEL, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error